Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows
Aclaris Therapeutics reported Q3 revenue of $3.30 million, exceeding analyst expectations of $1.59 million, despite a year-over-year decline. The net loss narrowed to $14.6 million, better than the anticipated $15.8 million. The company announced positive Phase 2a trial results for ATI-2138 in atopic dermatitis and plans further trials in 2026. Analysts maintain a "buy" rating on the stock, with a 12-month price target of $7.00, reflecting a potential upside of 67.7% from its recent closing price of $2.26.
)
Overview
- Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline
- Net loss for Q3 smaller than expected, reflecting better financial performance
- Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis
Outlook
- Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications
- Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026
- Aclaris expects cash runway to fund operations into H2 2028
Result Drivers
- NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024.
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Beat $3.30 $1.59
Revenue mln mln (6
Analysts
)
Q3 Net Beat -$14.61 -$15.80
Income mln mln (6
Analysts
)
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 7 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 67.7% above its November 5 closing price of $2.26
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
